A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505005-16-00

Acronym

MK-4830-002

Enrollment

Registered

2023-12-20

Start date

2022-07-27

Completion date

2024-10-01

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary peritoneal cancer/Fallopian tube cancer

Brief summary

Change from Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA)

Detailed description

Change from Baseline in Neoadjuvant ctDNA, Pathological Complete Response (pCR) Rate, Chemotherapy Response Score (CRS), Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an AE

Interventions

DRUGCARBOPLATIN

DRUGBEVACIZUMAB

DRUGMK-4830

DRUGPACLITAXEL

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGDOCETAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA)	—

Secondary

Measure	Time frame
Change from Baseline in Neoadjuvant ctDNA, Pathological Complete Response (pCR) Rate, Chemotherapy Response Score (CRS), Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an AE	—

Countries

Belgium, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026